Fig. 3
Meta-analysis comparing treatment and control groups stratified by the number of active drugs in OBT. RD, risk difference; CI, confidence interval. *Studies presenting data at week 24. 1Outcome: proportion of patients with < 200 HIV-1 RNA copies/mL. Outcome: proportion of patients with < 50 HIV-1 RNA copies/mL at week 48. Obs.1: BENCHMRK studies present data in a 96-week follow-up. Obs.2: SAILING study presented results stratified by active drugs in OBT only in 2 categories (< 2 and ≥ 2 active drugs in OBT). Data of category < 2 active drugs in OBT were presented in subgroup “1 active drug in OBT”